COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy of Human Placental Graft in Diabetic Foot Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03708029
Recruitment Status : Recruiting
First Posted : October 16, 2018
Last Update Posted : November 15, 2018
Information provided by (Responsible Party):

Brief Summary:
To determine the efficacy of full-thickness placental allograft in chronic wound healing

Condition or disease Intervention/treatment Phase
Diabetic Foot Other: Revita Allograft Not Applicable

Detailed Description:
To evaluate the efficacy of Revita full thickness placental allograft in improving wound closure rates and mean closure time in diabetic foot ulcers (DFUs) as compared to the current standards of wound care treatment

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Clinical Investigation Into the Efficacy of Full-thickness Human Placental Graft (Revita) in Diabetic Foot Ulcers
Actual Study Start Date : November 13, 2018
Estimated Primary Completion Date : April 30, 2019
Estimated Study Completion Date : June 30, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Intervention Treatment
Will receive Revita allograft for wound treatment
Other: Revita Allograft
Human placental allograft

No Intervention: Control
Will receive current standard of care for wound treatment

Primary Outcome Measures :
  1. Complete Wound Closure [ Time Frame: 12 weeks ]
    100% epithelization

Secondary Outcome Measures :
  1. Percent(%) Healed [ Time Frame: 12 weeks ]
    Percentage of wound healed

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female patients
  • 18-80 years old
  • Diagnosis of Type 1 or 2 Diabetes Mellitus
  • Foot ulcers >1cm2 and <25cm2 for 4 weeks or more prior to enrollment
  • Able to give consent to participate
  • Compliance with all aspects of protocol and follow-up

Exclusion Criteria:

  • Male and female patients younger than 18 years old
  • Male or female patients older than 80 years old
  • Smoking, and any additional health risk factors contraindicated with Revita use
  • Involvement in any other ongoing studies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03708029

Layout table for location contacts
Contact: Clinical Research Manager 4706160997
Contact: VP Clinical Development

Layout table for location information
United States, Florida
Gulf Coast Podiatry Recruiting
Pensacola, Florida, United States, 32503
Contact: Joseph Kiefer, DPM         
Principal Investigator: Joseph Kiefer, DPM         
United States, Louisiana
Louisiana Foot and Ankle Specialists Recruiting
Lake Charles, Louisiana, United States, 70605
Contact: Daniel Hall, DPM         
Principal Investigator: Daniel Hall, DPM         
Sub-Investigator: Mallory Przybylski, DPM         
United States, Pennsylvania
Springfield Hospital - Center for Wound Healing Recruiting
Springfield, Pennsylvania, United States, 19064
Contact: Chris Barrett, DPM         
Principal Investigator: Chris Barrett, DPM         
Sub-Investigator: Sneha Patel, DPM         
Sponsors and Collaborators
Layout table for investigator information
Study Director: Clinical Research Manager StimLabs
Layout table for additonal information
Responsible Party: StimLabs Identifier: NCT03708029    
Other Study ID Numbers: SLRV-POD-WC-001
First Posted: October 16, 2018    Key Record Dates
Last Update Posted: November 15, 2018
Last Verified: November 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases